Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of melphalan during treatment with melflufen + dexamethasone in relapsed/refractory multiple myeloma with impaired renal function
2018-000478-31Phase 2Terminated
- Sponsor
- Oncopeptides AB
- Start
- May 2018
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in multiple myeloma (MM), sponsored by Oncopeptides AB. Primary endpoint: PK parameters of melphalan. Started May 2018; status: terminated.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-000478-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000478-31.